Previous Close | 0.9500 |
Open | 0.9900 |
Bid | 0.0000 x 2200 |
Ask | 0.0000 x 1300 |
Day's Range | 0.9702 - 1.0982 |
52 Week Range | 0.7400 - 2.6700 |
Volume | |
Avg. Volume | 309,793 |
Market Cap | 23.747M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9600 |
Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for RKDA
Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 4,722,506 shares of its common stock (or common stock equivalents) at a purchase price of $1.05876 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the company agreed to is
Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the second quarter and first half of 2022.
Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the second quarter and first half of 2022 after market close on August 11, 2022.